CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34 enrolled
Drug / intervention
lidocaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02363803
NCT02363803N/ACompleted
CompareCT.gov

Predicting Individual Response to Analgesic Treatment in Painful Diabetic Neuropathy

Washington University School of Medicine·interventional·Posted Feb 16, 2015·Updated Nov 15, 2019

In Brief

A clinical study evaluating lidocaine and Placebo for Diabetes and 2 related conditions. Completed, enrolled 34 participants across 1 site.

Detailed Summary

Diabetic nerve pain \[painful diabetic peripheral neuropathy\] is a common medical problem with few reliably effective treatments. There is some evidence that sensory testing may help determine how individuals will respond to analgesic therapy. In this study, the investigators are evaluating the relationship between sensory testing and subject response to lidocaine infusion therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Peripheral Neuropathy, Pain
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 16, 2015
Enrollment StartFeb 1, 2015
Primary CompletionOct 17, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.4 years ago

Interventions

lidocainedrug

lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.

Placebodrug

Normal saline, approved for hypovolemia, and homeostasis.